OVERVIEW

Stock Information

Mar 23, 2019 10:22 AM EDT
Copyright Nasdaq. Minimum 15 minutes delayed.

Press Releases

Mar 06, 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Feb 27, 2019

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting

Feb 25, 2019

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

Feb 25, 2019

CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001

Upcoming Events & Recent Presentations

There are currently no events scheduled.

Mar 2019

CRISPR Therapeutics Corporate Presentation

Dec 2018

Preclinical Development of CTX120, an Allogeneic CAR-T Cell Product Candidate Targeting BCMA

Nov 2018

2018 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: CRISPR/Cas9 Enables the Efficient Production of Allogeneic CAR-T Cells Engineered to Contain Multiple Genome Edits to Enhance Therapeutic T Cell Function

May 2018

2018 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Poster: Allogeneic CAR-T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9

Apr 2018

2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR Engineered Anti-CD70 CAR-T Cells Demonstrate Potent Preclinical Activity Against Both Solid and Hematological Cancer Cells

Apr 2018

2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen